Pharmacokinetics (PK) of Human Immunoglobulin 10% Administered Subcutaneously Alone or Following Recombinant Human Hyaluronidase (rHuPH20) in Primary Immunodeficiency Disease (PIDD) Patients

被引：0
|
作者：
Rubinstein, A. [1 ,2 ]
Wasserman, R. L. [3 ]
Melamed, I. [4 ]
Stein, M. [5 ]
McCoy, B. [6 ]
Engl, W. [6 ]
Leibl, H. [6 ]
Gelmont, D. [7 ]
Schiff, R. I. [7 ]
Grossman, W. J. [7 ]
机构：
[1] Albert Einstein Coll Med, Bronx, NY 10467 USA
[2] Montefiore Hosp, Bronx, NY USA
[3] DallasAllergyImmunol, Dallas, TX USA
[4] IMMUNOe, Centennial, CO USA
[5] Allergy Associates Palm Beaches, N Palm Beach, FL USA
[6] Baxter BioSci, Vienna, Austria
[7] Baxter BioSci, Westlake Village, CA USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2011年 / 127卷 / 02期
关键词：
D O I：
10.1016/j.jaci.2010.12.848
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：AB213 / AB213
页数：1
相关论文
共 50 条
  • [31] Efficacy, Safety and Tolerability of Recombinant Human Hyaluronidase (RHUPH20)-Facilitated Subcutaneous (SC) Infusion of Immunoglobulin G (IGSC) (IGHY) in Adult Patients with Primary Immunodeficiencies (PI): Phase 3 Study Results
    Stein, Mark R.
    Wasserman, Richard L.
    Melamed, Isaac
    Rubinstein, Arye
    Puck, Jennifer
    Gupta, Sudhir
    Engl, Werner
    Leibl, Heinz
    McCoy, Barbara
    Yel, Leman
    Schiff, Richard I.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (03) : 380 - 381
  • [32] TOLERABILITY AND EFFICACY OF FACILITATED-SUBCUTANEOUS INFUSION OF HUMAN IMMUNOGLOBULIN G, 10%, AND RECOMBINANT HUMAN HYALURONIDASE (IGHY) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY (PI)
    Stein, M.
    Wasserman, R. L.
    Melamed, I.
    Rubinstein, A.
    Puck, J.
    Gupta, S.
    Engl, W.
    Leibl, H.
    McCoy, B.
    Gelmont, D.
    Schiff, R. I.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 135 - 136
  • [33] LONG-TERM EFFICACY OF RECOMBINANT HUMAN HYALURONIDASE (RHUPH20)-FACILITATED SUBCUTANEOUS (SC) INFUSION OF IMMUNOGLOBULIN G (IGG) (IGHY; HYQVIA) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCIES (PID): INFECTION RATES OVER THE COURSE OF TREATMENT
    Wasserman, R. L.
    Stein, M.
    Kobrynski, L.
    Gupta, S.
    Grant, J.
    Rubinstein, A.
    Engl, W.
    Mccoy, B.
    Leibl, H.
    Yel, L.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2015, 115 (05) : A102 - A102
  • [34] PREGNANCY REGISTRY TO COLLECT LONG-TERM SAFETY DATA FROM WOMEN TREATED WITH RECOMBINANT HUMAN HYALURONIDASE (rHuPH20)-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN G (IGHY; HYQVIA)
    Baumgartner, Irmgard
    Nagy, Andras
    Rabbat, Christopher
    McCoy, Barbara
    Leibl, Heinz
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2016, 36 (03) : 267 - 267
  • [35] Real-World Use of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IG) (IGHy) in Patients with Primary Immunodeficiency Disorders (PIDD)
    Rosenbach, Kevin P.
    Hughes, Stephanie
    Rozen, Leon
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (02) : AB220 - AB220
  • [36] SAFETY/TOLERABILITY OF THE NEW HUMAN SUBCUTANEOUS IMMUNOGLOBULIN (SCIG 20%) IN PEDIATRIC PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD)
    Paris, Kenneth
    Derfalvi, Beata
    Hussain, Iftikhar
    Haddad, Elie
    Darter, Amy
    Doralt, Jennifer
    Engl, Werner
    McCoy, Barbara
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2017, 37 (02) : 201 - 202
  • [37] Recombinant Human Hyaluronidase (Rhuph20) Facilitates Large Volume Subcutaneous Infusions of Immunoglobulin (Ig) At a Single Site by Increasing Local Fluid Dispersion and Reducing Induration in A Porcine Model
    Kang, David W.
    Jadin, Laurence
    Nekoroski, Tara
    Drake, Fred H.
    Zepeda, Monica L.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 (02) : 353 - 353
  • [38] Long-Term Tolerability and Safety Of Facilitated-Subcutaneous Infusion Of Human Immune Globulin G (IgG), 10%, and Recombinant Human Hyaluronidase (rHuPH20) (IGHy): A Phase 3 Extension Study In Patients With Primary Immunodeficiencies (PIs)
    Melamed, Isaac Reuven
    Wasserman, Richard L.
    Stein, Mark
    Rubinstein, Arye
    Puck, Jennifer M.
    Gupta, Sudhir
    Engl, Werner
    Leibl, Heinz
    Yel, Leman
    Schiff, Richard I.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB180 - AB180
  • [39] LONG-TERM SAFETY AND PHARMACOKINETICS OF FACILITATED-SUBCUTANEOUS INFUSION OF HUMAN IMMUNOGLOBULIN G, 10%, AND RECOMBINANT HUMAN HYALURONIDASE (IGHY): PHASE 3 EXTENSION STUDY IN PRIMARY IMMUNODEFICIENCY DISEASE
    Melamed, I.
    Wasserman, R. L.
    Stein, M.
    Rubenstein, A.
    Puck, J.
    Gupta, S.
    Engl, W.
    Leibl, H.
    Gelmont, D.
    Schiff, R. I.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 132 - 133
  • [40] LONG TERM SAFETY, EFFICACY AND TOLERABILITY OF RECOMBINANT HUMAN HYALURONIDASE [RHUPH20]-FACILITATED SUBCUTANEOUS (SC) INFUSION OF IMMUNOGLOBULIN G (IGG) (HYQVIA; IGHY) IN PEDIATRIC PATIENTS AGED <16 YEARS WITH PRIMARY IMMUNODEFICIENCIES (PID)
    Wasserman, Richard L.
    Melamed, Isaac
    Stein, Mark
    Kobrynski, Lisa
    Puck, Jennifer
    Gupta, Sudhir
    Engl, Werner
    McCoy, Barbara
    Leibl, Heinz
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2015, 35 (03) : 314 - 314
12345